Log in

Company updateMoneycontrol

Glenmark shares rise over 2% on US drug filing

Positive+403 sources

GreyOak summary

Glenmark Pharmaceuticals shares rallied 2.53% after its innovation arm, Ichnos Glenmark Innovation, filed an Investigational New Drug application with the US FDA for ISB 2301. This experimental trispecific antibody targets solid tumours like breast and lung cancer. The company plans to begin Phase 1 human trials in 2027 following favourable preclinical results.

What it affects

Source

Read the original at Moneycontrol

More Glenmark Pharmaceuticals news

All Glenmark Pharmaceuticals news →

We use cookies

Essential cookies keep GreyOak secure and functional. Optional cookies help improve your experience and platform performance. You can update your preferences anytime.

Cookie Policy